Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-09-28

AUTHORS

Y C Cheng, V Valero, M L Davis, M C Green, A M Gonzalez-Angulo, R L Theriault, J L Murray, G N Hortobagyi, N T Ueno

ABSTRACT

BACKGROUND: One of the proposed mechanisms of trastuzumab-induced regression of human epidermal growth factor receptor 2-positive (HER2+) tumours includes facilitation of antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates ADCC. We presented our pilot study of adding GM-CSF to trastuzumab in patients with trastuzumab-resistant HER2+ metastatic breast cancer. METHODS: Patients with HER2+ metastatic breast cancer that progressed after trastuzumab +/- chemotherapy were continued on trastuzumab 2 mg kg(-1) intravenous weekly and GM-CSF 250 μg m(-2) subcutaneous daily. Patients were assessed for response every 8 weeks. Treatment was continued until disease progression or intolerable toxicity. RESULTS: Seventeen patients were evaluable (median age 48 years, range 27-75 years). The median number of metastatic sites was 2 (range 1-3); the most common site was the liver (n=10). The median number of prior regimens for metastatic disease was 2 (range 1-5). No objective disease response was observed, but five patients (29%) had stable disease for a median duration of 15.8 (range 10-53.9) weeks. The most common adverse event was rash at the injection site. No grade 4 or irreversible adverse event was seen. CONCLUSION: The addition of GM-CSF to trastuzumab alone had a modest clinical benefit and acceptable safety profile in heavily pretreated patients with trastuzumab-resistant HER2+ metastatic breast cancer. More... »

PAGES

1331-1334

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bjc.6605918

DOI

http://dx.doi.org/10.1038/sj.bjc.6605918

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001610448

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20877352


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, erbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Granulocyte-Macrophage Colony-Stimulating Factor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pilot Projects", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA", 
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cheng", 
        "givenName": "Y C", 
        "id": "sg:person.013555426104.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013555426104.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Valero", 
        "givenName": "V", 
        "id": "sg:person.01075632431.92", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075632431.92"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davis", 
        "givenName": "M L", 
        "id": "sg:person.01145755571.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145755571.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Green", 
        "givenName": "M C", 
        "id": "sg:person.0772551177.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772551177.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gonzalez-Angulo", 
        "givenName": "A M", 
        "id": "sg:person.01066417500.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066417500.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Theriault", 
        "givenName": "R L", 
        "id": "sg:person.013042375417.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013042375417.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Murray", 
        "givenName": "J L", 
        "id": "sg:person.01013114134.60", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013114134.60"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hortobagyi", 
        "givenName": "G N", 
        "id": "sg:person.01365732165.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA", 
          "id": "http://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX, USA", 
            "Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "N T", 
        "id": "sg:person.010672310322.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010672310322.28"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrc1252", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037065448", 
          "https://doi.org/10.1038/nrc1252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01756182", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023532202", 
          "https://doi.org/10.1007/bf01756182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1202526", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001624052", 
          "https://doi.org/10.1038/sj.onc.1202526"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf01518520", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039057223", 
          "https://doi.org/10.1007/bf01518520"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02990841", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025096281", 
          "https://doi.org/10.1007/bf02990841"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.cgt.7700057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046522143", 
          "https://doi.org/10.1038/sj.cgt.7700057"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02990844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050476095", 
          "https://doi.org/10.1007/bf02990844"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-09-28", 
    "datePublishedReg": "2010-09-28", 
    "description": "BACKGROUND: One of the proposed mechanisms of trastuzumab-induced regression of human epidermal growth factor receptor 2-positive (HER2+) tumours includes facilitation of antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates ADCC. We presented our pilot study of adding GM-CSF to trastuzumab in patients with trastuzumab-resistant HER2+ metastatic breast cancer.\nMETHODS: Patients with HER2+ metastatic breast cancer that progressed after trastuzumab +/- chemotherapy were continued on trastuzumab 2 mg\u2009kg(-1) intravenous weekly and GM-CSF 250 \u03bcg\u2009m(-2) subcutaneous daily. Patients were assessed for response every 8 weeks. Treatment was continued until disease progression or intolerable toxicity.\nRESULTS: Seventeen patients were evaluable (median age 48 years, range 27-75 years). The median number of metastatic sites was 2 (range 1-3); the most common site was the liver (n=10). The median number of prior regimens for metastatic disease was 2 (range 1-5). No objective disease response was observed, but five patients (29%) had stable disease for a median duration of 15.8 (range 10-53.9) weeks. The most common adverse event was rash at the injection site. No grade 4 or irreversible adverse event was seen.\nCONCLUSION: The addition of GM-CSF to trastuzumab alone had a modest clinical benefit and acceptable safety profile in heavily pretreated patients with trastuzumab-resistant HER2+ metastatic breast cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bjc.6605918", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "103"
      }
    ], 
    "keywords": [
      "antibody-dependent cell-mediated cytotoxicity", 
      "metastatic breast cancer", 
      "trastuzumab-resistant HER2", 
      "breast cancer", 
      "GM-CSF", 
      "adverse events", 
      "median number", 
      "metastatic breast cancer patients", 
      "human epidermal growth factor receptor", 
      "common adverse events", 
      "acceptable safety profile", 
      "cell-mediated cytotoxicity", 
      "breast cancer patients", 
      "modest clinical benefit", 
      "irreversible adverse events", 
      "objective disease response", 
      "granulocyte-macrophage colony-stimulating factor", 
      "epidermal growth factor receptor", 
      "colony-stimulating factor", 
      "intravenous weekly", 
      "growth factor receptor", 
      "prior regimens", 
      "stable disease", 
      "intolerable toxicity", 
      "median duration", 
      "metastatic disease", 
      "metastatic sites", 
      "clinical benefit", 
      "safety profile", 
      "cancer patients", 
      "disease progression", 
      "common site", 
      "patients", 
      "trastuzumab", 
      "injection site", 
      "HER2", 
      "pilot study", 
      "factor receptor", 
      "cancer", 
      "disease", 
      "disease response", 
      "grade 4", 
      "weeks", 
      "regimens", 
      "chemotherapy", 
      "tumors", 
      "liver", 
      "progression", 
      "response", 
      "receptors", 
      "weekly", 
      "treatment", 
      "toxicity", 
      "cytotoxicity", 
      "duration", 
      "events", 
      "regression", 
      "facilitation", 
      "sites", 
      "addition", 
      "factors", 
      "study", 
      "number", 
      "benefits", 
      "profile", 
      "mechanism", 
      "trastuzumab-induced regression"
    ], 
    "name": "Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients", 
    "pagination": "1331-1334", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001610448"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bjc.6605918"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20877352"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bjc.6605918", 
      "https://app.dimensions.ai/details/publication/pub.1001610448"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:14", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_509.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bjc.6605918"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605918'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605918'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605918'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605918'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      22 PREDICATES      115 URIs      100 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bjc.6605918 schema:about N1052164c632c4a96a9e0663d5880cc3d
2 N2ede09a2b34f46c5b1983f3523ba90fd
3 N36d3326953774f2ab626dd87a1d329a2
4 N3be0b502f9134892acb8f3f22330fc4b
5 N66946a36ecbf4890bc5782e695024c7c
6 N7d2066fca93d44938a0754bea74acfdd
7 N89a23a3723c04d57b202ed178ee48ddf
8 N8a3f8c8b5fac468292bea4c95c705a1d
9 Nc4d67e3f46fd4541816a936b9a2f78aa
10 Nd70bdb0dc01f4c8fb3392557dbf057d4
11 Ndc9a26b71fec43c9b8cc717c4a12352c
12 Ne416a9bef8444924ab84fb4ab11efb94
13 Nef7f82240db84c2a980cde43325f1c81
14 Nf5931b386cc04613b1a9fbab3305860f
15 Nfa3ecce60e0f4c039d0b83a5b7bab635
16 anzsrc-for:11
17 anzsrc-for:1112
18 schema:author Na0ec4d6e77d345cea0edeac72d0efbe3
19 schema:citation sg:pub.10.1007/bf01518520
20 sg:pub.10.1007/bf01756182
21 sg:pub.10.1007/bf02990841
22 sg:pub.10.1007/bf02990844
23 sg:pub.10.1038/nrc1252
24 sg:pub.10.1038/sj.cgt.7700057
25 sg:pub.10.1038/sj.onc.1202526
26 schema:datePublished 2010-09-28
27 schema:datePublishedReg 2010-09-28
28 schema:description BACKGROUND: One of the proposed mechanisms of trastuzumab-induced regression of human epidermal growth factor receptor 2-positive (HER2+) tumours includes facilitation of antibody-dependent cell-mediated cytotoxicity (ADCC). Granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates ADCC. We presented our pilot study of adding GM-CSF to trastuzumab in patients with trastuzumab-resistant HER2+ metastatic breast cancer. METHODS: Patients with HER2+ metastatic breast cancer that progressed after trastuzumab +/- chemotherapy were continued on trastuzumab 2 mg kg(-1) intravenous weekly and GM-CSF 250 μg m(-2) subcutaneous daily. Patients were assessed for response every 8 weeks. Treatment was continued until disease progression or intolerable toxicity. RESULTS: Seventeen patients were evaluable (median age 48 years, range 27-75 years). The median number of metastatic sites was 2 (range 1-3); the most common site was the liver (n=10). The median number of prior regimens for metastatic disease was 2 (range 1-5). No objective disease response was observed, but five patients (29%) had stable disease for a median duration of 15.8 (range 10-53.9) weeks. The most common adverse event was rash at the injection site. No grade 4 or irreversible adverse event was seen. CONCLUSION: The addition of GM-CSF to trastuzumab alone had a modest clinical benefit and acceptable safety profile in heavily pretreated patients with trastuzumab-resistant HER2+ metastatic breast cancer.
29 schema:genre article
30 schema:inLanguage en
31 schema:isAccessibleForFree true
32 schema:isPartOf N734b3910956847bd9150375f159a8c80
33 N7c77ef501ec647ba9e8fcd803d452969
34 sg:journal.1017082
35 schema:keywords GM-CSF
36 HER2
37 acceptable safety profile
38 addition
39 adverse events
40 antibody-dependent cell-mediated cytotoxicity
41 benefits
42 breast cancer
43 breast cancer patients
44 cancer
45 cancer patients
46 cell-mediated cytotoxicity
47 chemotherapy
48 clinical benefit
49 colony-stimulating factor
50 common adverse events
51 common site
52 cytotoxicity
53 disease
54 disease progression
55 disease response
56 duration
57 epidermal growth factor receptor
58 events
59 facilitation
60 factor receptor
61 factors
62 grade 4
63 granulocyte-macrophage colony-stimulating factor
64 growth factor receptor
65 human epidermal growth factor receptor
66 injection site
67 intolerable toxicity
68 intravenous weekly
69 irreversible adverse events
70 liver
71 mechanism
72 median duration
73 median number
74 metastatic breast cancer
75 metastatic breast cancer patients
76 metastatic disease
77 metastatic sites
78 modest clinical benefit
79 number
80 objective disease response
81 patients
82 pilot study
83 prior regimens
84 profile
85 progression
86 receptors
87 regimens
88 regression
89 response
90 safety profile
91 sites
92 stable disease
93 study
94 toxicity
95 trastuzumab
96 trastuzumab-induced regression
97 trastuzumab-resistant HER2
98 treatment
99 tumors
100 weekly
101 weeks
102 schema:name Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
103 schema:pagination 1331-1334
104 schema:productId N505b843dd9a14fac8d4da4440b89afb0
105 N55e497833031424aaee08d7c1a215977
106 Nb69eab78629c44a9a053d060526e2dbb
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001610448
108 https://doi.org/10.1038/sj.bjc.6605918
109 schema:sdDatePublished 2021-11-01T18:14
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N90e1fc19316b4a58b463c8d334b67f39
112 schema:url https://doi.org/10.1038/sj.bjc.6605918
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N02b3cc66bb6d4eb4994e5e6f34a78853 rdf:first sg:person.0772551177.18
117 rdf:rest N5a1df2373fd3462fa2fb270278c5065e
118 N1052164c632c4a96a9e0663d5880cc3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Genes, erbB-2
120 rdf:type schema:DefinedTerm
121 N2ede09a2b34f46c5b1983f3523ba90fd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Antibodies, Monoclonal, Humanized
123 rdf:type schema:DefinedTerm
124 N36d3326953774f2ab626dd87a1d329a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Trastuzumab
126 rdf:type schema:DefinedTerm
127 N3be0b502f9134892acb8f3f22330fc4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 N3cd20df1e6b44870a09d95931fd7a39c rdf:first sg:person.01365732165.24
131 rdf:rest N56b7f49d5c4c40ba90de5614822021d1
132 N505b843dd9a14fac8d4da4440b89afb0 schema:name doi
133 schema:value 10.1038/sj.bjc.6605918
134 rdf:type schema:PropertyValue
135 N55e497833031424aaee08d7c1a215977 schema:name dimensions_id
136 schema:value pub.1001610448
137 rdf:type schema:PropertyValue
138 N56b7f49d5c4c40ba90de5614822021d1 rdf:first sg:person.010672310322.28
139 rdf:rest rdf:nil
140 N5a1df2373fd3462fa2fb270278c5065e rdf:first sg:person.01066417500.42
141 rdf:rest Nc8021bb97273468a99be7947dfe20a98
142 N66946a36ecbf4890bc5782e695024c7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Female
144 rdf:type schema:DefinedTerm
145 N734b3910956847bd9150375f159a8c80 schema:volumeNumber 103
146 rdf:type schema:PublicationVolume
147 N7c77ef501ec647ba9e8fcd803d452969 schema:issueNumber 9
148 rdf:type schema:PublicationIssue
149 N7d2066fca93d44938a0754bea74acfdd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Antineoplastic Combined Chemotherapy Protocols
151 rdf:type schema:DefinedTerm
152 N89a23a3723c04d57b202ed178ee48ddf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Pilot Projects
154 rdf:type schema:DefinedTerm
155 N8a3f8c8b5fac468292bea4c95c705a1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Breast Neoplasms
157 rdf:type schema:DefinedTerm
158 N90e1fc19316b4a58b463c8d334b67f39 schema:name Springer Nature - SN SciGraph project
159 rdf:type schema:Organization
160 N9509cd7006aa4eb1bd3e0669829f2a27 rdf:first sg:person.01145755571.50
161 rdf:rest N02b3cc66bb6d4eb4994e5e6f34a78853
162 Na0ec4d6e77d345cea0edeac72d0efbe3 rdf:first sg:person.013555426104.05
163 rdf:rest Nf14792f329474bfcbfcf3618f4a65d50
164 Nb69eab78629c44a9a053d060526e2dbb schema:name pubmed_id
165 schema:value 20877352
166 rdf:type schema:PropertyValue
167 Nc4d67e3f46fd4541816a936b9a2f78aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Neoplasm Metastasis
169 rdf:type schema:DefinedTerm
170 Nc8021bb97273468a99be7947dfe20a98 rdf:first sg:person.013042375417.45
171 rdf:rest Nf82b33d317d94885b556bc606c6deea7
172 Nd70bdb0dc01f4c8fb3392557dbf057d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Antibodies, Monoclonal
174 rdf:type schema:DefinedTerm
175 Ndc9a26b71fec43c9b8cc717c4a12352c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Aged
177 rdf:type schema:DefinedTerm
178 Ne416a9bef8444924ab84fb4ab11efb94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Drug Resistance, Neoplasm
180 rdf:type schema:DefinedTerm
181 Nef7f82240db84c2a980cde43325f1c81 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Granulocyte-Macrophage Colony-Stimulating Factor
183 rdf:type schema:DefinedTerm
184 Nf14792f329474bfcbfcf3618f4a65d50 rdf:first sg:person.01075632431.92
185 rdf:rest N9509cd7006aa4eb1bd3e0669829f2a27
186 Nf5931b386cc04613b1a9fbab3305860f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Middle Aged
188 rdf:type schema:DefinedTerm
189 Nf82b33d317d94885b556bc606c6deea7 rdf:first sg:person.01013114134.60
190 rdf:rest N3cd20df1e6b44870a09d95931fd7a39c
191 Nfa3ecce60e0f4c039d0b83a5b7bab635 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Adult
193 rdf:type schema:DefinedTerm
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
198 schema:name Oncology and Carcinogenesis
199 rdf:type schema:DefinedTerm
200 sg:journal.1017082 schema:issn 0007-0920
201 1532-1827
202 schema:name British Journal of Cancer
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01013114134.60 schema:affiliation grid-institutes:grid.240145.6
206 schema:familyName Murray
207 schema:givenName J L
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013114134.60
209 rdf:type schema:Person
210 sg:person.01066417500.42 schema:affiliation grid-institutes:grid.240145.6
211 schema:familyName Gonzalez-Angulo
212 schema:givenName A M
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066417500.42
214 rdf:type schema:Person
215 sg:person.010672310322.28 schema:affiliation grid-institutes:grid.240145.6
216 schema:familyName Ueno
217 schema:givenName N T
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010672310322.28
219 rdf:type schema:Person
220 sg:person.01075632431.92 schema:affiliation grid-institutes:grid.240145.6
221 schema:familyName Valero
222 schema:givenName V
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01075632431.92
224 rdf:type schema:Person
225 sg:person.01145755571.50 schema:affiliation grid-institutes:grid.240145.6
226 schema:familyName Davis
227 schema:givenName M L
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145755571.50
229 rdf:type schema:Person
230 sg:person.013042375417.45 schema:affiliation grid-institutes:grid.240145.6
231 schema:familyName Theriault
232 schema:givenName R L
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013042375417.45
234 rdf:type schema:Person
235 sg:person.013555426104.05 schema:affiliation grid-institutes:grid.240145.6
236 schema:familyName Cheng
237 schema:givenName Y C
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013555426104.05
239 rdf:type schema:Person
240 sg:person.01365732165.24 schema:affiliation grid-institutes:grid.240145.6
241 schema:familyName Hortobagyi
242 schema:givenName G N
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24
244 rdf:type schema:Person
245 sg:person.0772551177.18 schema:affiliation grid-institutes:grid.240145.6
246 schema:familyName Green
247 schema:givenName M C
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772551177.18
249 rdf:type schema:Person
250 sg:pub.10.1007/bf01518520 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039057223
251 https://doi.org/10.1007/bf01518520
252 rdf:type schema:CreativeWork
253 sg:pub.10.1007/bf01756182 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023532202
254 https://doi.org/10.1007/bf01756182
255 rdf:type schema:CreativeWork
256 sg:pub.10.1007/bf02990841 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025096281
257 https://doi.org/10.1007/bf02990841
258 rdf:type schema:CreativeWork
259 sg:pub.10.1007/bf02990844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050476095
260 https://doi.org/10.1007/bf02990844
261 rdf:type schema:CreativeWork
262 sg:pub.10.1038/nrc1252 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037065448
263 https://doi.org/10.1038/nrc1252
264 rdf:type schema:CreativeWork
265 sg:pub.10.1038/sj.cgt.7700057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046522143
266 https://doi.org/10.1038/sj.cgt.7700057
267 rdf:type schema:CreativeWork
268 sg:pub.10.1038/sj.onc.1202526 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001624052
269 https://doi.org/10.1038/sj.onc.1202526
270 rdf:type schema:CreativeWork
271 grid-institutes:grid.240145.6 schema:alternateName Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
272 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX, USA
273 schema:name Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA
274 Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX, USA
275 Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...